What Khondrion does

Khondrion is a clinical-stage biopharmaceutical company headquartered in Nijmegen, The Netherlands, developing therapies for primary mitochondrial diseases. Founded in 2014 by Prof. Jan Smeitink, the company is advancing sonlicromanol, a wholly owned, brain-penetrant small molecule with a unique triple mode of action: (1) redox modulation to restore cellular metabolism, (2) radical trapping to prevent ferroptotic cell death, and (3) selective mPGES-1 inhibition delivering anti-inflammatory effects. Sonlicromanol has received Orphan Drug Designation in both the US (for all inherited mitochondrial respiratory chain disorders) and the EU (for OXPHOS defects, MELAS, Leigh disease, and MIDD), plus FDA Rare Pediatric Disease Designation for MELAS. The compound is protected by patents granted in the US and EU covering the mPGES-1 anti-inflammatory mechanism, and Khondrion maintains a proprietary library of redox-modulating compounds for future pipeline indications.

The clinical pipeline centers on the pivotal Phase 3 KHENERFIN study (NCT06451757) in m.3243A>G primary mitochondrial disease, a 52-week registrational trial enrolling up to 220 adult patients across Europe, the UK, and the US at a dose of 90 mg twice daily as dispersible tablets. Supporting programs include the Phase 2 SON4PEM investigator-initiated study at Amsterdam UMC evaluating sonlicromanol for post-exertional malaise in post-COVID syndrome, the pediatric Phase 2 KHENERGYC study in children with genetically confirmed mitochondrial disease, and long-term data from the completed KHENERGYZE Phase 2b and ongoing KHENEREXT open-label extension, where patients have been dosed for over three years with improvements shown in NMDAS disease severity, fatigue, cognitive function, and mood. Clinical execution is anchored by Radboudumc and Amsterdam UMC, with a Scientific Advisory Board chaired by Sir Prof. Doug Turnbull.

Khondrion is privately held and pre-revenue, funded through non-dilutive grants (Netherlands Enterprise Agency Innovation Credit up to €5 million, EU Horizon 2020 SME Instrument Phase 2, EFRO), venture philanthropy (The Mito Fund, the venture philanthropy arm of UMDF), and Dutch patient foundations (Energy4All, Join4Energy, Road4Energy, Ride4Kids, Tim Foundation, Zeldzame Ziekten Fonds). The planned commercial model combines traditional hospital and specialty pharmacy distribution with territory-specific licensing, exemplified by the August 2025 exclusive licensing agreement with Medvisis Switzerland AG covering Switzerland and Liechtenstein. The company underwent a leadership transition in September 2025, appointing Jasper Levink (previously CFO and CBO) as CEO to succeed founder Jan Smeitink, who became Chairman of a newly formed five-member Supervisory Board.

Name

Khondrion

Legal name

Khondrion BV

Website

https://khondrion.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Khondrion is a clinical-stage biopharmaceutical company developing sonlicromanol, a brain-penetrant small molecule for primary mitochondrial diseases and post-COVID fatigue, currently advancing a pivotal Phase 3 trial in m.3243A>G patients across the US, UK, and Europe.

Ownership category

akta.pro rank

Product category

Clinical-Stage Biopharmaceutical Therapeutics

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Enzyme Replacement & Metabolic Disorder Therapies (HLAIAIAB)

Keywords

• Clinical-stage biopharmaceutical
• Mitochondrial disease therapeutics
• Orphan drug development
• Redox modulators
• Rare disease pipeline

Headquarters

HQ city

Nijmegen

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Sales: As a clinical-stage biopharma company, Khondrion's primary anticipated revenue stream is from sales of approved pharmaceutical products, specifically sonlicromanol for primary mitochondrial diseases and potentially post-COVID fatigue. The company is in late-stage development (Phase 3) and preparing for commercialization.
2. Licensing and Distribution Agreements: Khondrion generates revenue through licensing agreements granting commercialization rights to partners in specific territories. The company has entered an exclusive licensing agreement with Medvisis Switzerland AG for Switzerland and Liechtenstein, with potential for additional territorial partnerships.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Khondrion is a clinical-stage biopharmaceutical company developing sonlicromanol, a potentially first-in-class, brain-penetrant small molecule redox-modulator with a unique triple mode of action (reductive/oxidative distress modulation, anti-ferroptotic radical trapping, and selective mPGES-1 anti-inflammatory inhibition), for the treatment of primary mitochondrial diseases including m.3243A>G-related MELAS spectrum disorders and post-COVID fatigue with post-exertional malaise.

Product overview

Khondrion is a clinical-stage biopharmaceutical company with its lead product sonlicromanol, a potentially first-in-class brain-penetrant redox-modulator with anti-inflammatory properties targeting mitochondrial dysfunction. The company's clinical pipeline includes: the pivotal Phase 3 KHENERFIN study for m.3243A>G Primary Mitochondrial Disease; the SON4PEM Phase 2 study for post-COVID syndrome; the pediatric KHENERGYC Phase 2 study; and the completed KHENERGYZE Phase 2b study with its KHENEREXT open-label extension. The company is developing sonlicromanol as a potential treatment for primary mitochondrial diseases including MELAS spectrum disorders and post-COVID syndrome.

Differentiator

Problem solved

Functional benefit

Products and services

• Sonlicromanol Potentially first-in-class, brain-penetrant small molecule redox-modulator with a triple mode of action (reductive/oxidative distress modulation, anti-ferroptotic radical trapping, and selective mPGES-1 anti-inflammatory inhibition). Being developed as an investigational oral therapy for primary mitochondrial diseases including m.3243A>G-related MELAS spectrum disorders and maternally inherited diabetes and deafness (MIDD), as well as post-COVID fatigue with post-exertional malaise. Dosed as 90 mg dispersible tablets twice daily in Phase 3.

Quantifiable outcome

• Improvement in NMDAS disease severity score up to 6 points after 52 weeks treatment vs. natural history increase of 0.47 points/year indicating disease deterioration
• +3 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core.

• Medvisis Switzerland AGcoreChannel Partner/ Reseller/ Distributor · 18 August 2025Khondrion entered an exclusive licensing agreement with Medvisis Switzerland AG for the registration and commercialization of sonlicromanol in Switzerland and Liechtenstein for the treatment of Primary Mitochondrial Diseases. Medvisis receives exclusive rights to commercialize the product in its territory while Khondrion retains ownership of the underlying technology and development rights.
• RadboudumccoreStrategic or Co-development PartnerKhondrion collaborates with Radboud University Medical Center in Nijmegen for clinical trial execution. Dr. Mirian Jansen from the clinical metabolic department serves as principal investigator in the KHENERFIN Phase 3 study. The center has been involved in natural history studies and clinical development programs.
• Amsterdam University Medical CentercoreStrategic or Co-development PartnerKhondrion and Amsterdam UMC announced a collaboration to initiate a Phase 2 clinical trial of sonlicromanol for post-COVID symptoms. Prof. Michele van Vugt serves as Principal Investigator of the SON4PEM study at Amsterdam UMC, supported by ZonMw funding.
• International Mito Patients (IMP)coreStrategic or Co-development PartnerIMP is a global network of 25 national patient advocacy groups on 5 continents representing approximately 10,000 mitochondrial patients and their families. Khondrion collaborates with IMP for patient engagement, clinical trial support, and disease awareness initiatives. IMP Chair Paula Morandi expressed encouragement for the Phase 3 trial progress.
• Scientific Advisory BoardcoreStrategic or Co-development PartnerKhondrion established a Scientific Advisory Board with leading mitochondrial medicine experts including Sir Prof. Doug Turnbull (Chairman), Prof. Marni Falk, Prof. Michelangelo Mancuso, Prof. Shamima Rahman, Prof. Anu Suomalainen Wartiovaara, and Prof. Akira Ohtake. The board provides independent oversight, strategic guidance, and clinical development advice.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Reneo Pharmaceuticals: Clinical-stage biotech developing mavodelpar (REN001) for primary mitochondrial myopathies and fatty acid oxidation disorders. Reneo is a directly comparable peer in the primary mitochondrial disease therapeutic space with a similarly staged asset.
• Stealth BioTherapeutics: Stealth is a clinical-stage biotech developing elamipretide for primary mitochondrial disease including Barth syndrome and LHON. It is the most directly comparable peer, operating in the same mitochondrial-disease therapeutic area with a similar late-stage clinical asset and orphan regulatory strategy.
• Abliva (formerly NeuroVive Pharmaceutical): Swedish clinical-stage biotech developing KL1333 (now renamed) for primary mitochondrial disease. Abliva is a direct European mitochondrial-disease peer, running parallel registrational-stage programs in the same orphan indication.

Broad incumbents

• BridgeBio Pharma: Clinical and commercial-stage rare-disease biotech with multiple programs across genetic and metabolic disorders including mitochondrial conditions. A larger established player in the same orphan genetic-disease investment universe.
• PTC Therapeutics: Commercial-stage rare-disease company with a portfolio spanning Duchenne muscular dystrophy, aromatic L-amino acid decarboxylase deficiency, and Friedreich's ataxia. Comparable as a broad rare-genetic-disease incumbent with CNS/metabolic programs.
• Alexion (AstraZeneca Rare Disease): AstraZeneca's rare-disease unit commercializing Soliris, Strensiq, and Ultomiris across multiple ultra-rare metabolic and neurological disorders. Comparable as a large incumbent in the orphan drug commercial landscape that Khondrion would face or partner with at launch.
• Ultragenyx Pharmaceutical: Commercial-stage rare-disease company (notably where Khondrion's CMO Dr. Tom Pulles previously led EMEA Medical Affairs). Comparable as a larger rare-disease player pursuing multiple orphan metabolic and neurological indications with global commercialization.

Emerging players

• GenSight Biologics: Clinical-stage gene therapy company developing lenadogene nolparvovec for Leber Hereditary Optic Neuropathy (LHON), a mitochondrial genetic disorder. Directly comparable as a mitochondrial-disease drug developer with a different (gene therapy) modality.
• Minoryx Therapeutics: Clinical-stage biotech developing leriglitazone for X-linked adrenoleukodystrophy and Friedreich's ataxia. Comparable as a European late-stage rare-disease CNS/metabolic player with orphan drug designation.

Others

• Zogenix (now UCB, formerly Larodopa path): UCB acquired Zogenix in 2022 for Fintepla (Dravet syndrome). Comparable as a strategic acquirer / partner archetype for late-stage orphan CNS assets — a representative exit path for Khondrion at potential approval or partnering milestones.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/khondrion
• LinkedInlinkedin.com/company/khondrion

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Khondrion